title: [Development of renal affection in obese patients].
abstract: OBJECTIVE
  To characterize mechanisms, early markers and clinical signs of renal damage in obesity.
  
  
  METHODS
  The trial covered 29 males aged under 50 years (mean age 37.7+/-9.3 years) with abdominal obesity having neither carbohydrate metabolism disturbances nor chronic renal disease. All the patients were examined for microalbuminuria (MAU), serum level of leptin. Radionuclide scintigraphy of the kidneys with an acute captopril test, tests for serum concentrations of endothelin-1, homocistein, uric acid, ultrasound dopplerography of the brachial artery for assessment of endothelium-related vasodilation (ERVD) were made in 24 patients. In 9 patients MAU and ERVD were estimated after 3 months of valsartan treatment (80 mg/day).
  
  
  RESULTS
  MAU was detected in 62% patients, its rate increasing with elevation of serum leptin and endothelin concentration. Under normal values of creatininemia and GFR, obese patients showed deletion of renal functional reserve (RFR). Patients with low RFR had maximal uricemia and homocysteinemia, serum endothelin-1. Such patients demonstrated also abnormal ERVD. 3-month valsartan intake led to elevation of ERVD and disappearance of MAU.
  
  
  CONCLUSIONS
  Excessive leptin registered in obese patients provoked dysfunction of the endothelium of the intrarenal vessels manifesting with MAU, growth of endothelin-1 serum concentration and disorder of ERVD. This leads to unfavourable changes in filtrating function of the kidneys as seen from gradual deletion of RFR in the absence of hypercreatininemia. Elimination of MAU and ERVD disorders in obesity can be achieved by administration of angiotensin II receptor blockers.
authors.forename: E A
authors.initials: EA
authors.lastname: Saginova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Fedorova
authors.forename: V V
authors.initials: VV
authors.lastname: Fomin
authors.forename: S V
authors.initials: SV
authors.lastname: Moiseev
authors.forename: E G
authors.initials: EG
authors.lastname: Minakova
authors.forename: E P
authors.initials: EP
authors.lastname: Gitel'
authors.forename: L M
authors.initials: LM
authors.lastname: Samokhodskaia
authors.forename: I M
authors.initials: IM
authors.lastname: Kutyrina
authors.forename: N A
authors.initials: NA
authors.lastname: Mukhin
mesh_terms: D000328:Adult; D015897:Comorbidity; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D019332:Endothelin-1 / Q000097:blood; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology*; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology*; D012720:Severity of Illness Index
chemical_list: D019332:Endothelin-1; D020738:Leptin; D003404:Creatinine